Department of Orthopaedics and Physical Performance, University of Rochester Medical Center, Rochester, New York.
JAMA Netw Open. 2023 Jun 1;6(6):e2316769. doi: 10.1001/jamanetworkopen.2023.16769.
Little is known about the association of total knee replacement (TKR) removal from the Medicare inpatient-only (IPO) list in 2018 with outcomes in Medicare patients.
To evaluate (1) patient factors associated with outpatient TKR use and (2) whether the IPO policy was associated with changes in postoperative outcomes for patients undergoing TKR.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included data from administrative claims from the New York Statewide Planning and Research Cooperative System. Included patients were Medicare fee-for-service beneficiaries undergoing TKRs or total hip replacements (THRs) in New York State from 2016 to 2019. Multivariable generalized linear mixed models were used to identify patient factors associated with outpatient TKR use, and with a difference-in-differences strategy to examine association of the IPO policy with post-TKR outcomes relative to post-THR outcomes in Medicare patients. Data analysis was performed from 2021 to 2022.
IPO policy implementation in 2018.
Use of outpatient or inpatient TKR; secondary outcomes included 30-day and 90-day readmissions, 30-day and 90-day postoperative emergency department visits, non-home discharge, and total cost of the surgical encounter.
A total of 37 588 TKR procedures were performed on 18 819 patients from 2016 to 2019, with 1684 outpatient TKR procedures from 2018 to 2019 (mean [SD] age, 73.8 [5.9] years; 12 240 female [65.0%]; 823 Hispanic [4.4%], 982 non-Hispanic Black [5.2%], 15 714 non-Hispanic White [83.5%]). Older (eg, age 75 years vs 65 years: adjusted difference, -1.65%; 95% CI, -2.31% to -0.99%), Black (-1.44%; 95% CI, -2.81% to -0.07%), and female patients (-0.91%; 95% CI, -1.52% to -0.29%), as well as patients treated in safety-net hospitals (disproportionate share hospital payments quartile 4: -18.09%; 95% CI, -31.81% to -4.36%), were less likely to undergo outpatient TKR. After IPO policy implementation in the TKR cohort, there were lower adjusted 30-day readmissions (adjusted difference [AD], -2.11%; 95% CI, -2.73% to -1.48%; P < .001), 90-day readmissions ( -3.23%; 95% CI, -4.04% to -2.42%; P < .001), 30-day ED visits ( -2.45%; 95% CI, -3.17% to -1.72%; P < .001), 90-day ED visits (-4.01%; 95% CI, -4.91% to -3.11%; P < .001) and higher cost per encounter ($2988; 95% CI, $415 to $5561; P = .03). However, these changes did not differ from changes in the THR cohort except for increased TKR cost of $770 per encounter ($770; 95% CI, $83 to $1457; P = .03) relative to THR.
In this cohort study of patients undergoing TKR and THR, we found that older, Black, and female patients and patients treated in safety-net hospitals may have had lesser access to outpatient TKRs highlighting concerns of disparities. IPO policy was not associated with changes in overall health care use or outcomes after TKR, except for an increase of $770 per TKR encounter.
重要性:2018 年,将全膝关节置换术(TKR)从医疗保险仅限住院治疗(IPO)清单中移除,这对 Medicare 患者的术后结果的影响知之甚少。
目的:评估(1)与门诊 TKR 使用相关的患者因素;(2)IPO 政策是否与 TKR 术后结果的变化相关。
设计、设置和参与者:本队列研究纳入了来自纽约州规划和研究合作系统行政索赔的数据。纳入的患者为 2016 年至 2019 年在纽约州接受 TKR 或全髋关节置换术(THR)的 Medicare 付费服务受益人。使用多变量广义线性混合模型来确定与门诊 TKR 使用相关的患者因素,以及使用差异-差异策略来检查 IPO 政策与 Medicare 患者 THR 术后结果相比,与 TKR 术后结果的关联。数据分析于 2021 年至 2022 年进行。
暴露情况:2018 年实施 IPO 政策。
主要结果和措施:使用门诊或住院 TKR;次要结果包括 30 天和 90 天再入院、30 天和 90 天术后急诊就诊、非家庭出院和手术遭遇总成本。
结果:2016 年至 2019 年共进行了 37588 例 TKR 手术,涉及 18819 名患者,2018 年至 2019 年共进行了 1684 例门诊 TKR 手术(平均年龄[标准差],73.8[5.9]岁;12240 名女性[65.0%];823 名西班牙裔[4.4%],982 名非西班牙裔黑人[5.2%],15714 名非西班牙裔白人[83.5%])。年龄较大(例如,75 岁与 65 岁相比:调整差异,-1.65%;95%CI,-2.31%至-0.99%)、黑人(-1.44%;95%CI,-2.81%至-0.07%)和女性患者(-0.91%;95%CI,-1.52%至-0.29%)以及在安全网医院接受治疗的患者(不成比例份额医院支付四分位数 4:-18.09%;95%CI,-31.81%至-4.36%)进行门诊 TKR 的可能性较低。在 TKR 队列中实施 IPO 政策后,调整后的 30 天再入院率(AD,-2.11%;95%CI,-2.73%至-1.48%;P<0.001)、90 天再入院率(-3.23%;95%CI,-4.04%至-2.42%;P<0.001)、30 天急诊就诊率(-2.45%;95%CI,-3.17%至-1.72%;P<0.001)、90 天急诊就诊率(-4.01%;95%CI,-4.91%至-3.11%;P<0.001)和每次就诊的成本($2988;95%CI,$415 至$5561;P=0.03)均降低。但是,除了每次 TKR 就诊费用增加 770 美元(770;95%CI,83 美元至 1457 美元;P=0.03)外,这些变化与 THR 队列的变化不同。
结论和相关性:在这项对接受 TKR 和 THR 的患者进行的队列研究中,我们发现年龄较大、黑人、女性患者以及在安全网医院接受治疗的患者可能较少接受门诊 TKR,这突出了差异问题。IPO 政策与 TKR 后整体医疗保健使用或结果的变化无关,除了每次 TKR 就诊费用增加 770 美元。